VANTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANTIN (VANTIN).
Cefpodoxime proxetil is a semisynthetic third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Cefpodoxime proxetil is a prodrug that is de-esterified to the active metabolite cefpodoxime primarily by intestinal esterases. Cefpodoxime undergoes minimal hepatic metabolism; elimination is mainly renal via glomerular filtration and tubular secretion. |
| Excretion | Approximately 80-90% of cefpodoxime is excreted unchanged in the urine within 24 hours, mainly by glomerular filtration and tubular secretion. A small fraction is eliminated via bile and feces. |
| Half-life | The terminal elimination half-life in adults with normal renal function is about 2.2-2.8 hours. In children, it is approximately 1.5-2 hours. Prolonged half-life in renal impairment (up to 9-10 hours in severe impairment) requires dose adjustment. |
| Protein binding | About 21-29% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.6-1.2 L/kg, indicating distribution into extracellular fluid and some tissues. It penetrates well into blister fluid, bronchial mucosa, and tonsils. |
| Bioavailability | Oral bioavailability of cefpodoxime proxetil is about 50% (range 40-60%) when taken with food. It is increased by food (high-fat meal enhances absorption). The prodrug is rapidly desterified to active cefpodoxime. |
| Onset of Action | Peak plasma concentrations occur about 2-3 hours after oral administration. Clinical response typically begins within 24-48 hours for most infections. |
| Duration of Action | Bactericidal activity persists for approximately 12 hours, supporting a twice-daily dosing regimen. Clinical cure is achieved with standard 5-14 day courses depending on infection type. |
| Molecular Weight | 427.44 |
100-200 mg orally twice daily for 10-14 days for community-acquired pneumonia; 100 mg orally twice daily for 5-7 days for acute exacerbations of chronic bronchitis; 100 mg orally twice daily for 10 days for uncomplicated skin and skin structure infections; 100 mg orally twice daily for 3-7 days for uncomplicated urinary tract infections; 200 mg orally twice daily for 10 days for complicated urinary tract infections.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: 100 mg every 24 hours; CrCl <30 mL/min: 100 mg every 48 hours; hemodialysis: 100 mg after each dialysis session (administered 3 times weekly). |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C), use with caution. |
| Pediatric use | For acute otitis media, pharyngitis/tonsillitis, and impetigo: 10 mg/kg (max 400 mg) orally twice daily for 10 days; for uncomplicated urinary tract infections: 10 mg/kg (max 200 mg) orally twice daily for 3-7 days. |
| Geriatric use | No specific geriatric dose adjustment; base dosing on renal function. Monitor for adverse effects due to age-related renal impairment. |
| 1st trimester | Animal studies have not shown fetal harm; no adequate human studies in first trimester. Use only if clearly needed. |
| 2nd trimester | No evidence of risk in animal studies; human data limited. Use only if clearly needed. |
| 3rd trimester | No evidence of risk in animal studies; human data limited. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for VANTIN (VANTIN).
| Placental transfer | Cefpodoxime crosses the placenta; concentrations in fetal serum are approximately 10-15% of maternal serum concentrations. |
| Breastfeeding | Cefpodoxime is excreted in human milk in low concentrations. Use with caution in nursing mothers; potential for diarrhea, rash, and sensitization in infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to cefpodoxime or any cephalosporin antibiotic
| Precautions | Hypersensitivity reactions including anaphylaxis, Clostridioides difficile-associated diarrhea, Superinfection with prolonged use, Reduced efficacy in patients with renal impairment (dosage adjustment required), Potential for seizure activity if high doses are given to patients with renal impairment |
| Food/Dietary | Take with food to increase absorption. Avoid alcohol during therapy and for 72 hours after completion to prevent disulfiram-like reaction (nausea, vomiting, headache). No other significant food interactions. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not revealed evidence of harm to the fetus. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. No teratogenic effects reported in animal studies; however, as with all antibiotics, use in first trimester should be cautious due to potential effects on fetal development. |
| Fetal Monitoring | Monitor for signs of hypersensitivity reactions, diarrhea (Clostridium difficile infection), and superinfection. No specific fetal monitoring required, but routine prenatal care should continue. In pregnant women, monitor renal function as dose adjustment may be needed in impaired renal function. |
| Fertility Effects | No studies on fertility have been conducted in humans. Animal studies have not shown impaired fertility at clinically relevant doses. No known adverse effects on male or female fertility. |
| Clinical Pearls |
| VANTIN (cefpodoxime proxetil) is a third-generation oral cephalosporin with activity against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and many Enterobacteriaceae. It is commonly used for respiratory tract infections, otitis media, and urinary tract infections. Note: It has poor activity against Pseudomonas aeruginosa and Enterococcus spp. Administer with food to enhance absorption. Dosage adjustment required for CrCl <30 mL/min. |
| Patient Advice | Take this medication exactly as prescribed, usually twice daily for 5-14 days depending on infection. · Take with food to improve absorption and reduce stomach upset. · Complete the entire course even if you feel better to prevent resistance. · Shake the oral suspension well before each use and use a measuring device for accurate dosing. · Notify your doctor if you experience severe diarrhea, rash, or signs of allergic reaction. · Avoid alcohol during treatment and for 72 hours after last dose to reduce risk of disulfiram-like reaction. · Store tablets at room temperature; oral suspension can be refrigerated but do not freeze. |